Steve Brozak
Stock Analyst at WBB Securities
(0.45)
# 4,052
Out of 4,944 analysts
8
Total ratings
30%
Success rate
-15.49%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steve Brozak
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CDTX Cidara Therapeutics | Reiterates: Strong Buy | $45 | $62.00 | -27.42% | 2 | Jun 23, 2025 | |
| MRKR Marker Therapeutics | Reiterates: Strong Buy | $13 | $1.32 | +846.97% | 1 | Apr 1, 2025 | |
| OMER Omeros | Maintains: Strong Buy | $75 → $100 | $4.28 | +2,236.45% | 2 | Jun 18, 2021 | |
| RDHL RedHill Biopharma | Downgrades: Buy | $17,000 → $16,000 | $1.33 | +1,203,088.45% | 3 | May 28, 2021 |
Cidara Therapeutics
Jun 23, 2025
Reiterates: Strong Buy
Price Target: $45
Current: $62.00
Upside: -27.42%
Marker Therapeutics
Apr 1, 2025
Reiterates: Strong Buy
Price Target: $13
Current: $1.32
Upside: +846.97%
Omeros
Jun 18, 2021
Maintains: Strong Buy
Price Target: $75 → $100
Current: $4.28
Upside: +2,236.45%
RedHill Biopharma
May 28, 2021
Downgrades: Buy
Price Target: $17,000 → $16,000
Current: $1.33
Upside: +1,203,088.45%